Lucosky Brookman Represents Placement Agent, Spartan Capital Securities, LLC, in Registered Direct Offering and Concurrent Private Placement of $1 Million of Hancock Jaffe Laboratories, Inc. Common Stock and Warrants
Lucosky Brookman LLP (the "Firm") is pleased to announce that it successfully represented its client, Spartan Capital Securities, LLC ("Spartan"), as Placement Agent, in connection with the registered direct offering and concurrent private placement of approximately $1 million of Hancock Jaffe Laboratories, Inc. ("Hancock Jaffe" or the "Company") (NASDAQ: HJLI, HJLIW) common stock and warrants.
Hancock Jaffe specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. The registered direct offering provided for the sale of approximately 1,887,000 shares of common stock at a price of $0.405 per share. The private placement provided for the sale of approximately 1,887,000 five-year warrants to purchase shares of common stock at a purchase price of $0.125 per warrant with an exercise price of $0.405 per share. The registered direct offering and private placement both closed on April 28, 2020.
The Firm represented Spartan in their role as the exclusive placement agent for the registered direct offering and private placement. The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the registered direct offering was filed with the SEC. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus included in the registration statement, may be obtained from the SEC or from the Company.